Practice
Open Access
Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)
Kevin Brown, Matthew D. Seftel and Kevin A. Hay
CMAJ August 23, 2021 193 (33) E1300-E1302; DOI: https://doi.org/10.1503/cmaj.202907
Kevin Brown
Leukemia and Bone Marrow Transplant Program of British Columbia (Hay); Division of Hematology, Department of Medicine (Seftel, Hay), University of British Columbia; Canadian Blood Services (Seftel); Terry Fox Laboratory (Hay), British Columbia Cancer Research Institute, Vancouver, BC; Department of Internal Medicine (Brown), Max Rady College of Medicine, University of Manitoba, Winnipeg, Man.
MDMatthew D. Seftel
Leukemia and Bone Marrow Transplant Program of British Columbia (Hay); Division of Hematology, Department of Medicine (Seftel, Hay), University of British Columbia; Canadian Blood Services (Seftel); Terry Fox Laboratory (Hay), British Columbia Cancer Research Institute, Vancouver, BC; Department of Internal Medicine (Brown), Max Rady College of Medicine, University of Manitoba, Winnipeg, Man.
MD MPHKevin A. Hay
Leukemia and Bone Marrow Transplant Program of British Columbia (Hay); Division of Hematology, Department of Medicine (Seftel, Hay), University of British Columbia; Canadian Blood Services (Seftel); Terry Fox Laboratory (Hay), British Columbia Cancer Research Institute, Vancouver, BC; Department of Internal Medicine (Brown), Max Rady College of Medicine, University of Manitoba, Winnipeg, Man.
MD MSc
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)
Kevin Brown, Matthew D. Seftel, Kevin A. Hay
CMAJ Aug 2021, 193 (33) E1300-E1302; DOI: 10.1503/cmaj.202907
Jump to section
Related Articles
Cited By...
- No citing articles found.